DexCom, Inc. $DXCM Shares Bought by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 400.2% during the third quarter, Holdings Channel reports. The firm owned 77,492 shares of the medical device company’s stock after buying an additional 62,000 shares during the period. E. Ohman J or Asset Management AB’s holdings in DexCom were worth $5,214,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in DXCM. GAMMA Investing LLC lifted its stake in DexCom by 2.5% in the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock valued at $474,000 after buying an additional 169 shares during the last quarter. Inspire Investing LLC increased its holdings in shares of DexCom by 6.1% in the 3rd quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock worth $211,000 after acquiring an additional 180 shares during the period. Meiji Yasuda Asset Management Co Ltd. lifted its position in DexCom by 3.2% in the 1st quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company’s stock valued at $411,000 after purchasing an additional 187 shares during the last quarter. Integrated Wealth Concepts LLC lifted its position in DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares during the last quarter. Finally, STF Management LP boosted its stake in DexCom by 5.5% during the 2nd quarter. STF Management LP now owns 4,041 shares of the medical device company’s stock valued at $353,000 after purchasing an additional 211 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach acquired 18,200 shares of DexCom stock in a transaction on Monday, November 10th. The stock was bought at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the purchase, the chief operating officer owned 331,697 shares of the company’s stock, valued at $18,256,602.88. This represents a 5.81% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the transaction, the director directly owned 27,031 shares in the company, valued at approximately $1,569,690.17. This trade represents a 3.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 7,866 shares of company stock worth $448,177. Company insiders own 0.32% of the company’s stock.

DexCom Trading Up 0.2%

Shares of NASDAQ:DXCM opened at $67.57 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. The stock has a market capitalization of $26.35 billion, a price-to-earnings ratio of 37.54, a PEG ratio of 1.45 and a beta of 1.51. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25. The company has a 50 day moving average price of $64.07 and a 200 day moving average price of $73.11.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.04. The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The company’s revenue was up 21.6% compared to the same quarter last year. During the same period last year, the company posted $0.45 EPS. On average, research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on DXCM shares. Piper Sandler set a $75.00 price target on shares of DexCom and gave the company a “buy” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. cut their target price on DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Friday, October 31st. Royal Bank Of Canada reduced their price target on DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. Sanford C. Bernstein restated an “outperform” rating and set a $84.00 price objective on shares of DexCom in a research note on Monday, November 3rd. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of DexCom in a research note on Monday, December 22nd. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $86.61.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.